Comparison
Leuprorelin vs. Linaclotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
53714-56-0
851199-59-2
Molecular weight
1209.4 g/mol
1526.74 g/mol
Half-life
3 h
no data
Sequence
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtno data
Mechanism of action
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
0
of which in humans
4
0
Effects recorded
4
2
Open conflicts
1
0
Documented adverse events
3
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Leuprorelin and Linaclotid?
- Leuprorelin is classified as "Research other", while Linaclotid is classified as "Research other". Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Leuprorelin or Linaclotid?
- The highest available evidence level is "Human RCT" for Leuprorelin and "Human RCT" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Leuprorelin and Linaclotid in Germany and the United States?
- Germany: Leuprorelin — Prescription, Linaclotid — Prescription. United States: Leuprorelin — Prescription, Linaclotid — Prescription. These are factual summaries with source and review date on the individual pages.